Multaq - Thumbs down?

"A randomized trial of dronedarone (Multaq) in patients with permanent atrial fibrillation -- an unapproved indication for the antiarrhythmic drug -- has been stopped early because of increased cardiovascular events among patients receiving the product, its manufacturer said. Dronedarone, sold by sanofi-aventis, is currently approved to treat atrial flutter and paroxysmal or persistent -- but not permanent -- afib. The phase IIIb trial, called PALLAS, had enrolled 3,148 patients with permanent afib, with 70% showing symptoms for more than two years, according to a company statement. The same proportion also had heart failure at NYHA Class I to III at baseline."

Read full report here (From medpagetoday.com)